Abstracts Archive - Page 1389 of 2425 - ACR Meeting Abstracts

Abstract Number: 2752 • 2017 ACR/ARHP Annual Meeting
Risk of Hospitalizations for Venous Thromboembolism Among Patients with Selected Systemic Vasculitides: A Nationwide Analysis
Yiming Luo¹, Jiehui Xu², Yumeng Wen¹, Alvaro Ramos-Rodriguez¹, Changchuan Jiang¹, Shuyang Fang¹, Mustafa Kagalwalla¹ and Neha Ohri³, ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, ³Division of Rheumatology, Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Venous thromboembolism (VTE) contributes significantly to in-hospital morbidity and mortality. Previous studies have suggested that certain vasculitides, including granulomatosis with polyangiitis (GPA) and giant…
Abstract Number: 2753 • 2017 ACR/ARHP Annual Meeting
Brain Functional Connectivity Features of Pain Centralisation Relate to Degree of ‘Fibromyalgianess’ in Rheumatoid Arthritis
Neil Basu¹, Chelsea Cummiford², Eric Ichesco², Tony Larkin², Richard E. Harris², Alison Murray³, Gordon Waiter⁴ and Daniel J. Clauw⁵, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Aberdeen Brain Imaging Center, University of Aberdeen, Aberdeen, United Kingdom, ⁴Aberdeen Brain Imaging Centre, University of Aberdeen, Aberdeen, United Kingdom, ⁵Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Many rheumatoid arthritis (RA) patients continue to report pain despite excellent control of inflammation with immunotherapy regimes. Variable degrees of co-existing fibromyalgia (FM) may…
Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Elodie Perrodeau³, Pascal Cohen², Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Xavier Puéchal²⁰, Philippe Ravaud²¹, Luc Mouthon²² and Loïc Guillevin²⁰, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³Brest, Brest, France, ¹⁴Medecine Interne, CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²¹Hôpital Hôtel Dieu, Paris, France, ²²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
Abstract Number: 2755 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic DMARDs have varying mechanisms of action and may be associated with different infection risks. The perioperative time period is a particularly high-risk time…
Abstract Number: 2756 • 2017 ACR/ARHP Annual Meeting
Effect of Baseline and Change in Effusion-Synovitis on Cartilage Damage over 18 Months in Patients with Osteoarthritis and Meniscal Tear
Lindsey A. MacFarlane¹, Heidi Y. Yang², Jamie E. Collins³, Mohamed Jarraya⁴, Ali Guermazi⁵, Lisa A. Mandl⁶, Elena Losina³ and Jeffrey N. Katz⁷, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham & Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ⁴Musculoskeletal Radiology, Boston University School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Synovitis is a common feature in meniscal tear (MT) and osteoarthritis (OA). Synovitis has been associated with progression of cartilage damage in persons with…
Abstract Number: 2757 • 2017 ACR/ARHP Annual Meeting
Kidney and Skin Single-Cell RNA Sequencing in Lupus Nephritis Provides Mechanistic Insights and Novel Potential Biomarkers
Evan Der¹, Hemant Suryawanshi², Saritha Ranabothu³, Beatrice Goilav⁴, H. Michael Belmont⁵, Peter M. Izmirly⁶, Nicole Bornkamp⁵, Nicole Jordan⁷, Tao Wang¹, Ming Wu⁶, Judith A. James⁸, Joel M. Guthridge⁹, Soumya Raychaudhuri¹⁰, Thomas Tuschl¹¹, Jill P. Buyon¹² and Chaim Putterman¹³, ¹Albert Einstein College of Medicine, Bronx, NY, ²The Rockefeller University, New York, NY, ³Nephrology, Children's Hospital at Montefiore, Bronx, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷Montefiore Medical Center, New York, NY, ⁸Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Rockefeller University, New York, NY, ¹²Rheumatology, New York University School of Medicine, New York, NY, ¹³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Classification and treatment decisions in lupus nephritis (LN) are largely based on renal histology. Single-cell RNAseq (scRNAseq) analysis may accurately differentiate types of renal…
Abstract Number: 2758 • 2017 ACR/ARHP Annual Meeting
Response to JAK1/2 Inhibition with Baricitinib in “Candle”, “Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN-Mediated Autoinflammatory Diseases
Gina A. Montealegre Sanchez¹, Adam Reinhardt², Suzanne Ramsey³, Helmut Wittkowski⁴, Philip J Hashkes⁵, Sara Murias⁶, Yackov Berkun⁷, Susanne Schalm⁸, Jason A Dare⁹, Diane Brown¹⁰, Deborah L. Stone¹¹, Ling Gao⁹, Thomas L. Klausmeier¹², John D. Carter¹³, Robert Colbert¹⁴, Dawn C. Chapelle¹⁵, Hanna Kim¹⁵, Samantha Dill¹⁵, Adriana Almeida de Jesus¹, Paul Wakim¹⁶, A. Zlotogorski¹⁷, Seza Ozen¹⁸, Paul Brogan¹⁹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Faculty of Physicians of the University of Nebraska Medical Center, College of Medicine, Nebraska, NE, ³Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁴Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁵Pediatrics Rheumatology; Shaare Zedek Medical Center, Jerusalem, Israel, ⁶Hospital Infantil La Paz, Madrid, Spain, ⁷Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ⁸Hauner Children's Hospital LMU, Munich, Germany, ⁹University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁰Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ¹¹NHGRI/NIH, Bethesda, MD, ¹²Riley Hospital for Children, Indianapolis, IN, ¹³Division of Rheumatology, University of South Florida, Tampa, FL, ¹⁴NIAMS/NIH, Bethesda, MD, ¹⁵Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ¹⁶Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ¹⁷Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁹UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Monogenic autoinflammatory interferonopathies, including chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) and STING-associated vasculopathy with onset in infancy (SAVI), present with…
Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2760 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Ozan Unlu¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Paul R. Fortin⁵, Maria Gerosa⁶, Roger A. Levy⁷, Michelle Lopes⁸, Michelle Petri⁹, Ignasi Rodriguez¹⁰, Maria Tektonidou¹¹, Amaia Ugarte¹², Rohan Willis¹³, Doruk Erkan¹⁴ and , on Behalf of APS ACTION .¹⁵, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁷Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁸Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹⁰Rheumatology, Hospital Clinica, Barcelona, Spain, ¹¹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹²Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ¹⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁵., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 2761 • 2017 ACR/ARHP Annual Meeting
Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis
Ramadan A. Ali¹, He Meng¹, Srilakshmi Yalavarthi¹, Yogendra Kanthi¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: We have previously reported that antiphospholipid antibodies (aPL) activate neutrophils and thereby exaggerate neutrophil extracellular trap release (NETosis), which potentially contributes to the thrombotic…
Abstract Number: 2762 • 2017 ACR/ARHP Annual Meeting
Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Mériem Belhocine¹, Laetitia Coutte², Nicolas Martin Silva³, Nathalie Morel⁴, Gaelle Guettrot-Imbert⁴, Romain Paule⁴, Michel Dreyfus⁵, Micaela Fredi⁶, Odile Souchaud-Debouverie⁷, Jean Charles Piette⁸, Veronique Le Guern⁴ and Nathalie Costedoat-Chalumeau¹, ¹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ²Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Department of Internal Medicine, University Hospital Center of Caen, Caen, France, ⁴Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁵Department of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital Center of Caen, Caen, France, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Department of Internal Medicine, Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ⁸Department of Internal Medicine, Department of Internal Medicine, University Hospital Pitié-Salpétrière, Paris, France
Background/Purpose: The antiphospholipid syndrome (APS) is defined by a combination of arterial and/or venous thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies. There is a real…
Abstract Number: 2763 • 2017 ACR/ARHP Annual Meeting
mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE
Thomas Winans¹, Ryan Kelly², Zhi-Wei Lai³, Stephen Faraone², Paul E. Phillips⁴, Katalin Banki⁵ and Andras Perl³, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY, ⁴Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, ⁵Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Anti-phospholipid antibodies (aPL) constitute a diagnostic criterion and source of morbidity, termed anti-phospholipid syndrome (APS), in patients with or without systemic lupus erythematosus (SLE).…
Abstract Number: 2764 • 2017 ACR/ARHP Annual Meeting
Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease
Patricia Ruiz-Limon¹, Carlos Perez-Sanchez², Maria Ángeles Aguirre Zamorano², Irene Cecchi³, Nuria Barbarroja², Yolanda Jiménez-Gómez², Ivan Arias de la Rosa¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui⁴, Eduardo Collantes-Estévez², Maria Jose Cuadrado⁵ and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Monocytes are key players involved in the development of several autoimmune disease due to their capacity to modulate lipid metabolism, secrete inflammatory cytokines, chemokines,…
Abstract Number: 2765 • 2017 ACR/ARHP Annual Meeting
Centre of Pressure Characteristics during Walking in Individuals with and without First Metatarsophalangeal Joint Osteoarthritis
Hylton Menz¹, Maria Auhl², Jade Tan² and Shannon Munteanu¹, ¹La Trobe University, Bundoora, Australia, ²School of Allied Health, La Trobe University, Bundoora, Australia
Background/Purpose: Osteoarthritis of the first metatarsophalangeal joint (1st MTPJ OA) is a common and disabling condition characterised by symptoms of joint pain and stiffness, formation of…
Abstract Number: 2766 • 2017 ACR/ARHP Annual Meeting
Physical Therapy Vs. Internet-Based Exercise Training for Patients with Knee Osteoarthritis: Results of a Randomized Controlled Trial
Kelli Allen¹, Liubov Arbeeva², Leigh F. Callahan³, Yvonne M. Golightly⁴, Adam P. Goode⁵, Bryan Heiderscheit⁶, Carla Hill⁷, Kim Huffman⁸, Herbert Seversen⁹ and Todd A. Schwartz¹⁰, ¹Rheumatology, University of North Carolina at Chapel Hill and Durham VA Medical Center, Durham, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁴Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵O, Duke University, Durham, NC, ⁶Department of Orthopedics and Rehabilitation, University of Wisconsin, Madison, WI, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸School of Medicine, Division of Rheumatology, Immunology and Molecular Physiology and Durham VA Medical Center, Duke University, Durham, NC, ⁹Oregon Research Institute, Durham, OR, ¹⁰Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: The majority of adults with osteoarthritis (OA) are inactive, highlighting the need for continued efforts to promote regular engagement in exercise. Few studies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].